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Abstract 
Reduction of β-catenin (CTNNB1) destroying complex components, e.g. adenomatous 
polyposis coli (APC), induces β-catenin signaling and subsequently triggers activation of 
genes involved in proliferation and tumorigenesis. Though diminished expression of APC has 
organ specific and threshold dependent influence on the development of liver tumors in mice, 
the molecular basis is poorly understood. Therefore, a detailed investigation was conducted to 
determine the underlying mechanism in the development of liver tumors under reduced APC 
levels. Mouse liver at different developmental stages was analyzed in terms of β-catenin 
target genes including Cyp2e1, Glul and Ihh using real-time RT-PCR, reporter gene assays 
and immunohistological methods with consideration of liver zonation. Data from human 
livers with mutations in APC derived from FAP patients were also included. Hepatocyte 
senescence was investigated by determining p16INK4a expression level, presence of 
senescence-associated β-galactosidase (SA-β-Gal) activity and assessing ploidy. A β-catenin 
activation of hepatocytes does not always result in β-catenin positivity but unexpectedly also 
in mixed and β-catenin negative tumors. In summary, a senescence inducing program was 
found in hepatocytes with increased β-catenin levels and a positive selection of hepatocytes 
lacking p16INK4a, by epigenetic silencing, drives the development of liver tumors in mice with 
reduced APC expression (Apc580S mice). The lack of p16INK4a was also detected in liver 
tumors of mice with triggers other than APC reduction. 
Implications 
Epigenetic silencing of p16Ink4a in selected liver cells bypassing senescence is a general 
principle for development of liver tumors with β-catenin involvement in mice independent of 
the initial stimulus. 
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Introduction 
Genesis of hepatocellular carcinoma (HCC) is not fully understood, though several 
carcinogenic pathways involved in this process were identified (1) among them the 
Wnt/β-catenin pathway. Activated β-catenin (CTNNB1) signaling contributes to 
approximately 30% of HCCs (2, 3) and is characterised by nuclear and/or cytoplasmic 
staining of β-catenin (4) which contrasts to cell membranous staining of unaffected liver. 
Consequently, Wnt/β-catenin target genes, i.e. glutamine synthetase (Glul) (5), are 
upregulated in β-catenin positive HCCs. Induction of β-catenin signaling in HCCs is caused 
by gain of function mutations in β−catenin (6) or mutations in genes coding for components 
of the β-catenin destruction complex, i.e. AXIN1 (7) or AXIN2 (8). Though, mutations of 
adenomatous polyposis coli (APC) gene, a further constituent of β-catenin destruction 
complex, are rarely detected in primary liver cancer (9), methylation of APC promoter seems 
significant in HCC suggesting functional importance of altered APC levels (10). In contrast, 
other malignancies of gastrointestinal cancer, i.e. colon and rectal cancers, are strongly 
predisposed to APC germline mutations, as found in familial adenomatous polyposis (FAP, 
(11)). Recently, context specific responsiveness for Wnt/β-catenin signaling has been 
suggested necessary to develop cancer following APC reduction (12). Buchert reported 
development of HCCs in livers of aged homozygous Apc580S mice expressing reduced APC 
levels (13). Unexpectedly, HCCs of this model display a downregulation of the Wnt-target 
gene (14) Axin2, suggesting its reduction in tumors might have promoted HCC formation at 
the long latencies observed in these mice. 
However, the tumors lacked hypermethylation of Axin2 promoter (12). Moreover, additional 
events causing tumorigenesis in this model were still unclear as mutations in oncogenes, i.e. 
Hras, were not observed. Therefore, the mechanism of how APC reduction promotes HCC 
development remains ambiguous and important to elucidate. 
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Here we investigate potential mechanisms supporting development of HCCs in livers 
with reduced APC levels. To this end, we utilise Apc580S mice (13) exhibiting elevated 
β-catenin levels and investigate deregulation of Wnt signaling during all stages of HCC 
development. By comparing expression pattern in isolated hepatocytes and liver tissue of 
transgenic mice with different levels of β-catenin, which were generated with the help of the 
tet-inducible expression system, we inferred a concerted action of a senescence inducing 
program in hepatocytes with increased β-catenin levels and a positive selection for 
hepatocytes with loss of cell-cycle inhibitor p16INK4a (CDKN2A) (15) as driver for the 
development of liver tumors in Apc580S mice. 
 
Materials and Methods 
Mice 
An overview of transgenic mice is presented in Supplementary Table S1. Apc580S (13) mice, 
termed Apchomo, carry a homozygous floxed exon 14 Apc allele. Ctnnb1flox/flox (16) mice, 
termed Ctnnb1homo, were purchased from Jackson Laboratories. Three knock-out (KO) mice, 
ApcKO, Ctnnb1KO and ApcKO/Ctnnb1KO were obtained by interbreeding of floxed mice with 
liver specific inducible Cre mice (17) carrying inducible PtetCre-recombinase (LC-1) and 
tetracycline controlled transactivator (TALAP2) transgenes (18). Homozygous PtetCre-Apchomo 
mice were bred with homozygous TALAP2-Apchomo mice to obtain PtetCre-TALAP2-Apchomo 
which after induction by doxycycline withdrawal result in ApcKO (for breeding schema see 
Supplementary Fig.S1). Accordingly, interbreeding was performed with Ctnnb1homo and 
combined Apchomo/Ctnnb1homo mice leading to Ctnnb1KO or ApcKO/Ctnnb1KO mice 
(Supplementary Tab.S1). Conductin+/lacZ mice in which the reporter enzyme β-galactosidase is 
controlled by endogenous Conductin (Axin2) promoter were interbred with Apchomo mice and 
other lines specified above to obtain Apchetero/Conductin+/lacZ, Apchomo/Conductin+/lacZ and 
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ApcKO/Conductin+/lacZ mice, respectively. Mice used in proliferation tests received a unique 
BrdU injection (i.p.,10mM, 0.01ml/g body weight) two hours before killing. 
Human tissue samples 
Human specimens were provided by the Tissue Bank of the National Center for Tumour 
Diseases (Heidelberg, Germany, ethics proposal 206/2005, University Heidelberg). 14 
formalin-fixed, paraffin-embedded liver specimens mostly taken from partial hepatectomies 
for liver metastases of colorectal cancer excised far from the metastases were investigated. 
Seven patients had clinically known FAP. 
Histochemistry and immunohistochemistry 
Immunohistochemistry was performed as described (19, 20). Briefly, 5-µm paraffin sections 
were dewaxed with xylol and hydrated through downward alcohol series. Antigen retrieval 
was assessed by microwaving in citrate buffer (pH 6.0). Slides were equilibrated in Tris-
buffered saline (pH 7.4), quenched with H2O2, blocked with biotin/avidin, and goat serum and 
Blocking Reagent (VECTORTM M.O.M. Immunodetection Kit) for mouse antibodies 
respectively, and incubated with primary antibodies (listed in Supplementary Tab.S2) 
overnight at 4°C. Corresponding biotinylated secondary antibodies were coated for 1 hour at 
room temperature. After washing slides were incubated with extravidin-POD conjugate and 
washed three times before staining with 3,3’-diaminobenzidine-tetrahydrochloride (DAB). 
POD oxidises DAB producing a brown precipitate. For p16INK4a immunohistochemistry 
human liver sections were stained automatically by a Ventana Nexes autostainer (Ventana, 
Tucson, USA) using CINtec® p16 (E6H4) immunohistochemistry. 
Senescence associated β-galactosidase (SA-β-Gal) 
Frozen liver samples were cut and mounted on Superfrost plus slides (Menzel, Braunschweig, 
Germany). Slides were dried 1 hour at room temperature and fixed with 0.5% glutaraldehyde 
in PBS 5 min at room temperature. After washing in PBS slides were incubated in 40 mM 
Na2HPO4, 40 mM citrate pH 6.0, stained overnight at 37°C with 1 mg/ml 5-bromo-4-chloro-
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3-indolyl-beta-D-galactoside (X-Gal) in 40 mM citric acid, sodium  phosphate, pH 6.0, 5 mM 
potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl and 2 mM MgCl2.and 
counterstained with hematoxylin.  
Reporter enzyme 
Sections were fixed in 2% paraformaldehyde and 0.2% glutaraldehyde in PBS pH 7.4  for 30 
min at room temperature, washed three times for 15 min with 2 mM MgCl2, 0.01% Nonidet 
P-40 in PBS and stained with 1 mg/ml X-Gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6 for 36–40 
h at 37 °C in the dark. Slides were counterstained with nuclear fast red. 
Isolation of hepatocytes, cell culture and transfection 
Primary hepatocytes were isolated and cultivated as described (20) by collagenase perfusion 
(21). Pericentral and periportal hepatocytes were isolated by a modified digitonin/collagenase 
perfusion technique (22, 23) and transfected with TOP-Gau reporter plasmids (24) using 
Effectene (Qiagen). Apc silencing in vitro was achieved by transfection with Apc siRNA 
(APCMSS202103, APCMSS202104, APCMSS202105, Invitrogen, 4nM) using Interferin 
(PeqLab). 
Gaussia luciferase assay 
Gaussia luciferase activity was measured in 10 µl supernatant of transfected hepatocytes with 
50 μl assay reagent on Orion-II microplate luminometer (Titertek-Berthold). 
RNA isolation and quantitative real-time reverse transcription PCR (qRT-PCR) 
Total RNA was isolated using PeqGOLD RNA Pure isolation system (Peqlab). RNA quality 
was assessed by gel electrophoresis and purity was estimated using the A260/A280 ratio. 
Concentration was adjusted to 0.5 mg/ml. qRT-PCR was performed as described (20) using 
primers listed in Supplementary Table S3. RNA load was normalised with the housekeeping 
gene cyclophilin (Ppia). Standard curves of serial dilutions from total RNA were used for 
transforming ct-values to concentration values depicted as arbitrary units. 
Methylation-specific PCR 
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DNA from tumor and surrounding liver tissue was isolated using NucleoSpin tissue kit 
(Macherey&Nagel). DNA methylation was tested with the bisulfite conversion method using 
the EZ DNA-Methylation-Gold kit (Zymo Research) and p16Ink4a promoter-specific primers 
(25) Supplementary Table S3). 
Clinical Chemistry 
Alanine aminotransferase (ALAT) and glutamate dehydrogenase (GLDH) were measured on 
an automated clinical chemistry analyzer (Modular PPE, Roche). 
Flow cytometry  
Hepatocytes were counted and 200,000 cells were resuspended in 100 μl wash buffer (PBS, 
5% FCS). After washing, 500 μl prechilled ethanol (-20°C) was added slowly with continuous 
mixing avoiding agglutination. Hepatocytes were kept on ice, washed twice with 1 ml 
PBS/5% FCS and incubated for 1 hour with RNAse A (1mg/ml PBS) at 37°C. Suspensions 
were brought up to 200 μl with PBS/5% FCS and 20 μl propidium iodide (1 mg/ml) was 
added. This hepatocyte suspension was measured on a flow cytometer (FACScan, BD 
Biosciences) for determining the ploidy grade. 
Statistical analysis 
All data are expressed as mean + S.E.M. Statistical analysis was performed by Student’s t-test 
or Mann-Whitney test using SigmaPlot 11 (SSP Science). The accepted level of significance 
was set at p<0.05. 
 
Results 
Activation of β−catenin initiates AXIN2 expression in selected/individual HCCs of aged 
Apchomo mice 
Using liver sections β-catenin signaling was investigated by immunohistochemistry in 
hepatocytes of young (8 weeks) and aged (10 months) Apchomo and compared to ApcKO mice 
representing a positive control for β-catenin activation (Figs.1A-D). This staining displayed 
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only few hepatocytes with activated β-catenin (nuclear expression) both in liver tissue from 
young Apchomo mice and tissue adjacent to tumors in aged mice. Liver tumors and their 
prestages in aged Apchomo mice exhibit, unexpectedly, a highly heterogeneous β-catenin 
staining in the same animal. Both β-catenin negative (Fig.1C,C’) and β-catenin positive 
(Fig.1D,D’) tumors were detected. Moreover, if tumors contained activated β-catenin they 
always displayed membrane-bound β-catenin providing a mixed phenotype, while an 
exclusively nuclear or cytoplasmic staining was never detectable. 
Quantification of the universal and direct Wnt/β-catenin target gene, Axin2 mRNA level in 
liver tissue extracts (Fig.1E), expectedly revealed a significant elevation in Apchomo and ApcKO 
and a decrease by trend in Ctnnb1KO mice (only 2 animals were investigated due to sudden 
early death of Ctnnb1KO mice) and a significant decrease in ApcKO/Ctnnb1KO mice compared 
to controls (both heterozygous and wild-type mice). In contrast, Axin2 mRNA levels in tumor 
extract (containing several tumors) were not significantly altered (Fig.1E). However, re-
evaluation of macroscopically visible tumors and subsequent resection of individual tumors of 
each liver revealed different individual Axin2 mRNA levels (Fig.1F). Thereby, in the same 
animal either up- or downregulation of the β-catenin responsive target Axin2 occur in 
individual HCCs.To functionally validate activation of β-catenin signaling in vitro we 
transfected a TCF-reporter, which allows monitoring activity of β-catenin triggers, in isolated 
primary hepatocytes (Fig.1G). Hepatocytes from Apchomo mice show a 5fold induction of 
Gaussia luciferase activity compared to controls, and in turn represent about one-fifth of 
luciferase activity obtained in ApcKO mice (Fig.1G), thus supporting Axin2 mRNA data.  
In vivo we also confirmed the elevated activation of β-catenin signaling in Apchomo mice 
utilizing the Wnt reporter mouse Conductin+/lacZ in which the reporter gene β-galactosidase is 
expressed in response to the endogenous Conductin (Axin2) promoter. In 
Apchetero/Conductin+/lacZ mice  β-galactosidase was detected only in pericentral hepatocytes as 
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a weak spot-like staining within the nucleus of the first row of cells around central veins and 
rarely in the second row, while midzonal or periportal hepatocytes were never positively 
marked (Fig.1H). In Apchomo mice (Fig.1J) the expression zone expanded and staining 
intensity increased. Here, several individual midzonal hepatocytes show β-galactosidase 
activity.  
β-catenin target genes are heterogenously expressed in tumors and lesions  
We examined expression of common β-catenin target genes, Glul and Cyp2e1 (Cytochrome 
P450 2E1) (Fig.2A), representing classical pericentrally (pc) expressed proteins within livers 
of Apchomo mice at different ages. Additionally, we inspected the pattern of typical periportally 
(pp) expressed proteins, carbamoyl phosphate synthetase I (CPS) and E-cadherin, which are 
expected to be conversely localized to pc-specific proteins (Fig.2A). Liver tissue of Apchomo 
mice showed age-dependent up-regulation of β-catenin target genes, Cyp2e1 and Glul, 
supporting data from Buchert and collegues (12), who investigated five-months-old mice. The 
cellular proportion of the pericentral expression type in the zonal expression pattern starts to 
increase at age 3 weeks and is nearly completed at age 8 weeks. Later on, in mice, over five 
months old (Fig.2A), first cancerous lesions appear. Although there was a slight increase of 
hepatocytes exhibiting nuclear/cytoplasmic β-catenin in aged Apchomo mice, GLUL expression 
never spread over the whole lobulus.  
The shifted zonal expression pattern of pericentral and periportal proteins in liver parenchyma 
of Apchomo mice as a result of a continuous moderate activation of β-catenin signaling raised 
the question whether zonal shifting in liver parenchyma also occurs in patients with APC-
repressing mutations. Thus we examined the zonal expression pattern of GLUL in paraffin 
sections of livers of FAP patients (Fig.2B). In six out of seven FAP liver samples enlargement 
of the GLUL positive zone was detected. In two of these six samples GLUL positive focal 
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nodular hyperplasia was demonstrated (Fig.2B, top right), whereas GLUL positive nodules 
were not present in controls. 
Precancerous lesions and tumors of aged Apchomo mice, however, feature surprising 
heterogeneity regarding the expression of the β-catenin target genes, Glul and Cyp2e1 (Fig.3). 
As expected from nuclear/cytoplasmic β-catenin staining pattern and Axin2 mRNA 
quantification tumors with pericentral, periportal or the mixed expression program were 
detected within an individual animal (Fig.3). 
p16INK4a expression is regulated by β-catenin and loss of p16INK4a is characteristic for all 
tumors and precancerous lesions 
The mechanism driving carcinogenesis in Apchomo mice seems obscure, because β-catenin 
dependent hepatocyte proliferation is supposed not to be cell-autonomous (26) and tumors 
with homogenously nuclear β-catenin staining were not found in our experiments. Moreover, 
hyperproliferation neither of hepatocytes carrying nuclear or cytoplasmic β-catenin nor of pc- 
re-programmed GLUL positive hepatocytes occurs in Apchomo mice (Supplementary Fig.S2). 
A pronounced proliferation in non-tumorous liver parenchyma was detected in livers of ApcKO 
mice only (Supplementary Fig.S2,C) compared to coeval Apchomo and control mice 
(Supplementary Fig.S2A,B). However, the hyperproliferation in ApcKO mice is accompanied 
with ruin of hepatocytes by necrosis (Fig.7A,B; black arrows). However, preliminary 
microarray experiments comparing the mRNA expression pattern of pericentral hepatocytes 
from Apchomo mice to periportal hepatocytes from Apchetero mice, indicate alterations of tumor 
suppressor levels in pericentral hepatocytes. Furthermore, tumor suppressor p16INK4a was 
recently identified as a β-catenin target gene (27). Both results suggest p16INK4a as a possible 
key regulator for tumorigenesis in Apchomo mice. Consequently, we analyzed p16INK4a 
immunohistochemically and detected a very high cytoplasmic amount of p16INK4a in nearly all 
hepatocytes in aged Apchomo mice independently of their acinar location (Supplementary 
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Fig.S3,S4). Livers of FAP patients were also examined concerning expression of p16INK4a. 
Hereby both stainings manually performed with monoclonal antibody D7D7 used for 
detection of p16INK4a negative lesions in mice (not shown) and automatically performed with 
monoclononal antibody E6H4 (CINtec® p16,) (Supplementary Fig.S3) detected a pronounced 
incidence of p16INK4a in all livers samples of FAP patients compared to normal liver. Thereby 
a preference of p16INK4a expression in pericentral areas was observed in both FAP livers and 
controls (frames in Supplementary Fig.S3J,K and the corresponding magnifications J’ and 
K’). 
Simultaneously, loss of p16INK4a protein in all mouse liver tumors and precancerous lesions 
(Fig.4A) was detected. Serial sections of liver tissue from mice at age 10 months or older 
showing macroscopically visible tumors corroborate the p16INK4a negativity of tumors and 
prestages independently on whether a periportal or pericentral expression program was 
followed (Fig.4A). Cells within the p16INK4a negative tumors proliferate which is shown by 
BrdU incorporation (Supplementary Fig.S2E,E’). In contrast tumor surrounding hepatocytes 
which are characterized by high p16INKa expression do not proliferate (Supplementary 
Fig.S2E’). 
To confirm p16INK4a protein deficiency as a general hallmark of HCCs in mice with abnormal 
β-catenin signaling, we stained liver sections harbouring tumors, which initial causative event 
had been identified as activating mutations in exon 3 of the CTNNB1 proto-oncogene, leading 
to constitutively active Wnt/β-catenin signaling, ((28), Fig.4C) and tumors, which developed 
after transfection of Apcflox/flox mice using a virally encoded Cre-recombinase ((29), Fig.4B). 
All tumors including those with different genesis were p16INK4a protein negative. In contrast, 
liver tumors of aged Apchomo mice displayed no reduction of other tumor suppressors i.e. 
p19ARF, p15INK4b or p21CIP1 (data not shown). Higher p16Ink4a mRNA expression level was 
found in pericentral hepatocytes of Apchomo mice (moderate activation of β-catenin signaling) 
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and hepatocytes of ApcKO mice (highest β-catenin signaling) compared to hepatocytes of 
Apchetero mice (low β-catenin signaling) (Fig.5B). 
Cause of p16INK4a deficiency in tumors of Apchomo mice  
The downregulation of p16INK4a protein in tumors of Apchomo mice matches data on kidney 
(30), showing that only bypassing senescence caused by p21CIP1 triggers renal tumors in 
Apchomo mice. In liver p16Ink4a silencing seems to meet this function.  
To validate if p16INK4a reduction is epigenetically regulated p16Ink4a promoter methylation was 
examined. Only 1 out of 7 tumors displayed a methylation-specific PCR product (Fig.5A). 
Next, we investigated the transcriptional level by quantifying p16Ink4a mRNA by qRT-PCR. 
No reduction of p16Ink4a mRNA was detected in tumors compared to surrounding normal liver 
tissue of Apchomo mice (Fig.5B, right). In contrast, paradoxically, an increase of p16Ink4a 
mRNA level was detected in all tumors lacking p16Ink4a promoter methylation (Fig.5B and 
Supplementary Fig.S5). The p16INK4a reduction seems post-transcriptionally regulated, 
probably by increased degradation of p16INK4a protein which would explain increased p16Ink4a 
mRNA levels as compensatory mechanism. Recently, p16INK4a degradation was suggested to 
occur ubiquitin-independently by PSME3 proteasome (31). Hence, we quantified Psme3 in 
tumor and liver extracts and found an up-regulation exclusively in tumor tissue (Fig.5C). 
Tumor T2-2 in which the p16Ink4a promoter is methylated shows no up-regulation of Psme3 
but demonstrates alternatives for p16INK4a reduction in certain cases. Accordingly, this tumor 
was excluded for statistical analysis of Psme3 mRNA. 
Consequences of altered p16INK4a expression 
Overexpression of tumor suppressors, e.g. p16INK4a, leads to induction of senescence 
associated β-galactosidase (SA-β-Gal; GLB1) (32, 33), activation of the facultative stem cell 
compartment, oval cells, in phases with proliferation demand (33) and polyploidisation of 
hepatocytes (33). In all stages of life more SA-β-Gal was detected in cryosections of Apchomo 
compared to Apchetero mice (Fig.6B). However, stronger upregulation of SA-β-Gal was found 
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in livers of ApcKO mice (Fig.6C) and the strongest reactivity was observed in tissue 
surrounding tumors and precancerous lesions (Fig.6D). Isolated primary hepatocytes of aged 
mice revealed in FACS analysis an increase of >16N-ploidy in Apchomo and ApcKO mice 
(Fig.6E), whereas hepatocytes with 4N-ploidy decreased significantly in ApcKO mice and by 
trend in Apchomo mice. Immunohistological stainings with anti-pan-cytokeratin antibody 
specific for oval cells (34), show their activation in Apchomo mice starting at age 5 months. In 
livers of mice older than 10 months both around macroscopically identifiable tumors and 
areas of cancer-prestages a border of oval cells was visible (Fig.6J,K, arrows). Hence the 
question arose what trigger, preferably produced by tumors, could activate oval cell 
compartment in Apchomo mice. 
Recently, Indian hedgehog (IHH) was confirmed as an activator of hepatic stem cells 
produced by dying hepatocytes (35). We found Ihh up-regulated both in cultured hepatocytes 
after Apc siRNA treatment (Fig.6F) and in ApcKO mice (Fig.6F) thus confirming Ihh increase 
in livers of AhCre-ApcKO mice (36). These data combined with a trend of Ihh reduction in 
hepatocytes of Ctnnb1KO mice confirm Ihh as direct target of β-catenin (37). The up-
regulation of Ihh mRNA level in tumors (Fig.6F) supports a role as death signal of 
hepatocytes, and cell damage should be expected. 
Evidence of hepatocyte damage 
Necrotic cell death occurs in ApcKO mice of every age but also in old Apchomo mice with 
tumors and prestages (Fig.7A,B). Additionally apoptotic death, featured by numerous 
Councilman bodies (Fig.7C), seems to play a role in hepatocyte loss of Apchomo mice, at least 
in aged mice, even though caspase-3 detection failed in all liver slides (not shown). As 
elevated liver enzymes in serum clearly indicate necrotic loss of hepatocytes, we measured 
characteristic liver parameters in serum of Apchomo, Apchetero and ApcKO mice. Although a 
slight, non-significant raise of ALAT and GLDH activities was detected age-dependently in 
Apchomo up to the age of 12 months (Fig.7D,F), a significant difference of these enzyme 
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activities as shown for old mice (Fig.7B,D) between Apchomo and Apchetero mice (controls) 
could be measured at all these ages (not shown). In contrast, serum levels of tumor harbouring 
mice and ApcKO mice were increased up to 10fold compared to age related Apchomo mice 
(Fig.7A-D). 
Additionally DNA damage was observed by anti-γ-H2AX staining in all tumors and their 
prestages (Fig.7K). Moreover, large quantities of γ-H2AX positive nuclei were detected in 
ApcKO mice (Fig.7J). 
 
Discussion 
Reduced APC expression leads to permanent activation of β-catenin and consequently, to 
upregulation of Wnt/β-catenin target genes and a pericentral expression program (12, 28, 38). 
Conversely, Hras mutations cause a periportal expression program (28). Unexpectedly, livers 
of Apchomo mice, providing a model of half-maximal β-catenin activation, develop 
phenotypically different tumors. Some of them are distinguished by the expression of the 
Wnt-target gene Glul and others by detection of E-cadherin, which is actually downregulated 
by sufficient β-catenin activation and belongs to the periportal expression program. Other 
Wnt-target genes, i.e. Axin2, are reduced or unchanged in such tumors ((12), present study). 
Likewise, the periportally expressed protein CPS is heterogeneously expressed.  
The tumor suppressor p16INK4a, recently identified as a β-catenin target gene (27), was 
completely lost at protein level in all tumors and precancerous lesions investigated here and 
results in bypassing senescence as recently also found in human HCC and hepatoblastoma 
(39, 40). 
Our data suggest the epigenetic silencing of p16Ink4a in selected liver cells is a common factor 
for development of liver tumors. Firstly, APC reduction leads to overexpression of p16INK4a in 
the unaffected healthy liver of Apchomo mice and in hepatocytes of ApcKO mice with highly 
 16
activated β-catenin signaling. Subsequently, elevated p16INK4a induces senescence and 
protects from tumorigenesis as recently shown by others for pre-malignant hepatocytes in 
mice (41). Necessarily, increased ALAT and GLDH levels in Apchomo mice indicate loss of 
pericentrally programmed hepatocytes, which culminates in permanent proliferative stress of 
residual hepatocytes, being still senescent by p16INK4a overexpression. Thereby no fully 
replicative senescence seems to occur, because growth and physiological function of liver of 
Apchomo mice are not limited up to a critical age of about 10 months when tumors develop. 
Because the replicative capacity of hepatocytes is impaired by p16INK4a overexpression, a 
physiologically required hepatocyte replacement generates a selective pressure, both forcing 
the initiation of p16Ink4a silencing in selected populations of hepatocytes and promoting 
subsequent proliferation of clusters of p16INK4a negative hepatocytes. We hypothesize this 
sequence of events because no single p16INK4a negative hepatocyte was detected in younger 
animals before precancerous lesions occur and hyperproliferation does also not occur by 
moderate/half-maximal activated hepatocytes.  
It seems irrelevant which metabolic program (pericentral/periportal phenotype) is followed by 
p16Ink4a silenced cells. The most relevant process responsible for silencing of p16Ink4a function 
is the specific p16INK4a removal, most likely by PSME3 mediated proteasomal digestion.  
The p16INK4a overexpression induced by diminished APC levels supports faster ageing and 
death of hepatocytes, which therefore contain a diminished proliferative capacity. A similar 
explanation can be supposed to pericentral hepatocytes, which have a continuous β-catenin 
signaling (42), and might also be relevant in liver parenchyma of FAP patients as shown here 
by GLUL expression. P16INK4a up-regulation as a consequence of APC-repressing mutations 
also occurs in hepatocytes of FAP patients and likely protects from liver cancer in early stages 
of life in the majority of cases. The higher incidence of hepatoblastoma in children with FAP 
(43) and the frequent occurrence of p16INK4a loss in hepatoblastoma (40) underscores the 
significance of the tumor supressor p16INK4a in β−catenin activated liver parenchyma. 
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The escalation of ALAT and GLDH concentrations in ApcKO mice indicates a massive decay 
of hepatocytes probably causing sudden death of ApcKO mice 10 to 14 days after conditional 
knockout. The strong γ-H2AX staining in ApcKO mice verifying the replicative stress in ApcKO 
hepatocytes supports this suggestion.  
The IHH signal delivered by dying hepatocytes is obviously not sufficient to activate an 
adequate number of oval cells to replace lost cells. This also applies to tumors whose elevated 
Ihh levels might follow, additionally to activation by β-catenin, damage induced signals, 
similarly as reported on radiated hepatocytes (44). Even if sufficient oval cells were activated, 
their subsequent differentiation into hepatocytes would ultimately end in their decline.  
Summarizing, our data suggest the epigenetic silencing of p16Ink4a in selected liver cells 
bypassing senescence is a common principle for the development of tumors in mouse liver 
with β-catenin involvement independent of the initial stimulus. 
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Figure legends 
 
Figure 1 
Activation of canonical β-catenin signaling in liver of Apchomo mice 
A-D) Immunohistochemistry of mouse liver sections with anti-β-catenin antibody.  
Though some hepatocytes with nuclear β-catenin are detected in liver parenchyma of young 
Apchomo mice (A,A’), the staining pattern is mainly comparable to normal liver (not shown) 
with β-catenin detection at hepatocyte membrane. A pronounced nuclear staining of β-catenin 
is induced in ApcKO mice (B,B’). Aged Apchomo mice have clusters of hepatocytes with nuclear 
β-catenin staining (C and right edge in C’) and have both tumor prestages and tumors without 
nuclear β-catenin (C’) and with nuclear β-catenin (D,D’). C’ and D’ represent larger 
magnifications of framed areas in C and D. Scale bar, A,B,C,D, 1200 µm; A´,B´,C´,D´, 40 
µm. 
E-F) Quantification of Axin2 mRNA (E) in livers of different transgenic mice and tumor 
tissue of aged Apchomo mice by qRT-PCR; *, p<0.05, n>4, t-test, and (F) in single individual 
tumors of aged Apchomo mice. T represents individual tumors, i.e. T2-1 indicates tumor 2 in 
mouse 1. 
G-J) Differential activation of β-catenin. (G) Activity of the Top-Gau luciferase reporter 
(containing two sets of three copies of TCF binding site and a soluble Gaussia princeps 
luciferase) displays differential β-catenin activation in vitro in cultured primary hepatocytes 
(hep) of Apchomo, ApcKO and Ctnnb1KO mice related to control mice 48 hours post transfection, 
p<0.05, n=4 (For each group hepatocytes of four different animals were used), Mann-Whitney 
test. 
Demonstration of Wnt/β-catenin signaling in liver sections of Apchetero/Conductin+/lacZ mice 
(H) and Apchomo/Conductin+/lacZ mice (J) by enzyme-immunohistochemistry of β-
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galactosidase using X-Gal as substrate displays a distinct turquoise reaction product. Scale 
bar, 50 µm. 
 
Figure 2  
Immunohistochemistry of marker proteins zonally expressed in mouse and human liver  
(A) Spreading of pericentral (GLUL, CYP2E1) and periportal (CPS, E-cadherin) specific 
proteins over the liver lobe in Apchomo mice at different ages 
Using rabbit anti-CPS I, mouse anti-GLUL, mouse anti-E-cadherin and rabbit anti-CYP2E1 
antibodies the distribution of indicated pericentral and periportal proteins is 
immunohistochemically demonstrated (brown, DAB). Liver sections of 8 week old Apchetero 
mice, used as controls, show the localisation of the proteins in normal mouse liver, because no 
differences were detected between C57BL/6 and Apchetero mouse liver at different ages (not 
shown). Central veins were indicated by cv, portal tracts by pv. Bar represents 100 µm. 
(B) Distribution of the pericentral marker enzyme GLUL in human liver sections 
Immunohistochemistry with anti-GLUL antibody (brown, DAB) was performed on 
representative normal human liver sections and liver sections of FAP patients.  
 
Figure 3 
Expression of typical pericentral and periportal proteins in tumors and precancerous lesions in 
aged Apchomo mice (>10 months) 
Serial liver sections of different tumor harbouring mice were immunohistochemically stained 
using antibodies against GLUL and CYP2E1, which represent pericentrally expressed 
proteins in normal liver and CPS and E-cadherin, which exhibit periportally expressed 
proteins in normal mouse liver. From left to right the following HCC phenotypes are shown: 
GLUL positive, GLUL negative, mixed phenotype and tumor prestages. Scale bar, 100 µm. 
 
Figure 4  
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P16INK4a expression in HCCs of mouse liver 
(A) Serial liver sections of tumor-containing Apchomo (13) mouse, (B) Apcflox/flox mouse in vivo 
transfected with adenoviral Cre (29) and (C) mice with chemically induced HCCs (28) were 
incubated either with anti-GLUL and anti-p16INK4a or anti-E-cadherin and anti-p16INK4a 
antibodies. Positively labelled signals are brown (DAB). Chemically induced tumors had been 
generated by a N-nitrosodiethylamine/ phenobarbital initation protocol, with a single i.p. 
dosage of the nitrosamine (90µg/g body weight) at 6  weeks of age followed by 
phenobarbital-containing diet (0.05%) for 6 months. Scale bar, 100 µm. 
 
Figure 5  
Cause of p16INK4a reduction in mouse liver tumors  
A) Methylation-specific PCR proved epigenetic silencing of p16Ink4a promoter. 
DNA of seven different tumors was examined by PCR using primers specific for methylated 
(m) and unmethylated (um) p16Ink4a-promoter. As controls a methylated DNA (positive-m; 
Zymed research) and DNA of tumor T1-1 surrounding liver tissue of an Apchomo mouse 
(homo-m, homo-um) were used. Abbreviations: see legend of Fig.1B. 
B) Quantification of p16Ink4a expression in isolated hepatocytes and liver tissue extracts by 
qRT-PCR. 
Mean relative mRNA content of pericentral hepatocytes of Apchomo (pc-Apchomo, n=6), 
hepatocytes of ApcKO (hep-ApcKO, n=3) and Apchomo (hep-Apchomo, n=3) mice, and Apchomo 
liver tissue (tissue-Apchomo, n=6) and tumor tissue of Apchomo mice (n=7) was compared to the 
mean value provided by hepatocytes of 5 control animals which were used as reference. The 
highest, but equal, p16Ink4a expression was measured in tumor and surrounding liver tissue of 
Apchomo mice, *, p<0.05, Mann-Whitney test. Tissue of tumor 2-2 possesses decreased 
p16INK4a mRNA compared to control (see Supplementary Fig.S5). 
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C) QRT-PCR of Psme3 mRNA in liver extracts of indicated mice and tumors of Apchomo mice 
and in separately isolated individual tumors (see also legend Fig.1), *, p<0.05, Mann-Whitney 
test. 
 
Figure 6 
Signals of senescence in Apchomo mice 
(A-D) Enzyme-histochemistry of SA-β-Gal in liver cryosections of control (Apchetero) (A), 
Apchomo (B), ApcKO (C) and tumor-containing aged Apchomo mice (D). The turquoise color is 
the reaction product of SA-β-Gal activity with substrate X-Gal at pH 6.0. Dotted line in D 
marks the border between tumor, visible on the upper right edge, and non-tumor. Scale bar, 50 
µm. 
Altered hepatocyte ploidy and DNA content respectively was determined by flow cytometry 
analysis using propidium iodide staining (E). Apchetero mice possess more hepatocytes with 4N 
DNA content than ApcKO mice. Hepatocytes with higher ploidy, >16N, were over-represented 
in Apchomo and ApcKO mice compared to controls (Apchetero), *, p<0.05, t-test. (F) Ihh mRNA 
was measured by qRT-PCR in isolated hepatocytes and in extracts of whole liver. Data 
represent fold change in positive direction for induction and in negative direction for 
repression of Ihh mRNA. The ratio of Ihh mRNA in Apchetero mouse liver normalised to 
cyclophilin mRNA represents the benchmark, *, p<0.05, Mann-Whitney test. 
Abbreviations: hep, total hepatocytes; pc, pericentral hepatocytes; tissue, liver tissue; hep-wt-
Apc-si, C57BL/6-hepatocytes transfected with Apc siRNA. 
(G-K) Depiction of oval cells by cytokeratin immunoreactivity. 
Liver sections of Apchetero (G) and Apchomo (H-K) mice, each 10 months old, were 
immunohistochemically stained with an anti-cytokeratin antibody combined to a biotinylated 
secondary antibody (brown; DAB) Arrows indicate the remarkable border of oval cells 
surrounding tumor prestages. Scale bar, 50 µm. 
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Figure 7 
Evidence of hepatocyte damage in Apchomo and ApcKO mice 
(A-C) Hematoxylin/Eosin staining of liver sections of ApcKO (A) and old Apchomo mice (B,D) 
demonstrating the ruin of hepatocytes by necrosis (black arrows in A and B) and by apoptosis 
(black arrows in C).  
(D-G) Serum enzyme activity of GLDH (D) and ALAT (F) in Apchomo and ApcKO mice at 
different ages and compared to activities in control mice (Apchetero) as indicated (E,G), Mann-
Whitney test, *, p<0.02. 
(E-G) Immunohistochemistry with rabbit anti-γ-H2AX detects DNA damage in (H) control 
(Apchetero), (J) ApcKO and (K) Apchomo mice (brown nuclei, DAB). The dashed line in (G) 
marks the border to the tumor (*). Scale bar, 50 µm. 
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